vs
Chatham Lodging Trust（CLDT）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Chatham Lodging Trust的1.9倍（$127.1M vs $67.7M），再鼎医药同比增速更快（17.1% vs -9.8%），过去两年再鼎医药的营收复合增速更高（20.8% vs -0.5%）
查塔姆住宿信托是一家专注于投资、持有及运营高端长住型和精选服务类酒店物业的房地产投资信托，主要布局美国高需求的城市及城郊市场，服务商务与休闲旅客群体，追求长期稳定的现金流收益。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CLDT vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.9倍
$67.7M
营收增速更快
ZLAB
高出26.9%
-9.8%
两年增速更快
ZLAB
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $67.7M | $127.1M |
| 净利润 | $4.6M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 15.9% | -54.6% |
| 净利率 | 6.8% | — |
| 营收同比 | -9.8% | 17.1% |
| 净利润同比 | 369.9% | — |
| 每股收益（稀释后） | $0.05 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLDTZLAB
| Q4 25 | $67.7M | $127.1M | ||
| Q3 25 | $78.4M | $115.4M | ||
| Q2 25 | $80.3M | $109.1M | ||
| Q1 25 | $68.6M | $105.7M | ||
| Q4 24 | $75.1M | $108.5M | ||
| Q3 24 | $87.2M | $101.8M | ||
| Q2 24 | $86.5M | $100.1M | ||
| Q1 24 | $68.4M | $87.1M |
净利润CLDTZLAB
| Q4 25 | $4.6M | — | ||
| Q3 25 | $3.5M | $-36.0M | ||
| Q2 25 | $5.4M | $-40.7M | ||
| Q1 25 | $1.5M | $-48.4M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $4.3M | $-41.7M | ||
| Q2 24 | $6.8M | $-80.3M | ||
| Q1 24 | $-5.2M | $-53.5M |
毛利率CLDTZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | 40.7% | 61.5% | ||
| Q3 24 | 44.7% | 64.1% | ||
| Q2 24 | 46.1% | 64.9% | ||
| Q1 24 | 38.9% | 61.4% |
营业利润率CLDTZLAB
| Q4 25 | 15.9% | -54.6% | ||
| Q3 25 | 12.7% | -42.3% | ||
| Q2 25 | 14.8% | -50.3% | ||
| Q1 25 | 12.1% | -53.3% | ||
| Q4 24 | 7.5% | -62.6% | ||
| Q3 24 | 14.3% | -66.6% | ||
| Q2 24 | 16.3% | -76.0% | ||
| Q1 24 | 1.4% | -80.7% |
净利率CLDTZLAB
| Q4 25 | 6.8% | — | ||
| Q3 25 | 4.5% | -31.2% | ||
| Q2 25 | 6.7% | -37.3% | ||
| Q1 25 | 2.2% | -45.8% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | 4.9% | -40.9% | ||
| Q2 24 | 7.9% | -80.2% | ||
| Q1 24 | -7.6% | -61.4% |
每股收益（稀释后）CLDTZLAB
| Q4 25 | $0.05 | $-0.05 | ||
| Q3 25 | $0.03 | $-0.03 | ||
| Q2 25 | $0.07 | $-0.04 | ||
| Q1 25 | $-0.01 | $-0.04 | ||
| Q4 24 | $-0.08 | $-0.09 | ||
| Q3 24 | $0.05 | $-0.04 | ||
| Q2 24 | $0.10 | $-0.08 | ||
| Q1 24 | $-0.15 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.4M | $689.6M |
| 总债务越低越好 | $338.9M | — |
| 股东权益账面价值 | $740.8M | $715.5M |
| 总资产 | $1.2B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.46× | — |
8季度趋势，按日历期对齐
现金及短期投资CLDTZLAB
| Q4 25 | $24.4M | $689.6M | ||
| Q3 25 | $13.2M | $717.2M | ||
| Q2 25 | $17.2M | $732.2M | ||
| Q1 25 | $18.6M | $757.3M | ||
| Q4 24 | $20.2M | $779.7M | ||
| Q3 24 | $19.3M | $616.1M | ||
| Q2 24 | $10.6M | $630.0M | ||
| Q1 24 | $72.3M | $650.8M |
总债务CLDTZLAB
| Q4 25 | $338.9M | — | ||
| Q3 25 | $338.8M | — | ||
| Q2 25 | $351.2M | — | ||
| Q1 25 | $381.1M | — | ||
| Q4 24 | $406.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CLDTZLAB
| Q4 25 | $740.8M | $715.5M | ||
| Q3 25 | $749.4M | $759.9M | ||
| Q2 25 | $754.1M | $791.7M | ||
| Q1 25 | $754.7M | $810.8M | ||
| Q4 24 | $758.2M | $840.9M | ||
| Q3 24 | $765.3M | $667.7M | ||
| Q2 24 | $766.5M | $704.2M | ||
| Q1 24 | $765.0M | $762.2M |
总资产CLDTZLAB
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.2B | $1.2B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $985.3M | ||
| Q2 24 | $1.3B | $987.4M | ||
| Q1 24 | $1.3B | $988.4M |
负债/权益比CLDTZLAB
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $64.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 13.90× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CLDTZLAB
| Q4 25 | $64.1M | $-26.0M | ||
| Q3 25 | $25.6M | $-32.0M | ||
| Q2 25 | $22.1M | $-31.0M | ||
| Q1 25 | $4.2M | $-61.7M | ||
| Q4 24 | $73.8M | $-55.8M | ||
| Q3 24 | $28.8M | $-26.8M | ||
| Q2 24 | $25.2M | $-42.2M | ||
| Q1 24 | $6.9M | $-90.1M |
自由现金流CLDTZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率CLDTZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度CLDTZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率CLDTZLAB
| Q4 25 | 13.90× | — | ||
| Q3 25 | 7.24× | — | ||
| Q2 25 | 4.10× | — | ||
| Q1 25 | 2.73× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.78× | — | ||
| Q2 24 | 3.68× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLDT
| Occupancy | $61.5M | 91% |
| Hotel Other | $4.2M | 6% |
| Food And Beverage | $1.8M | 3% |
| Hotel | $1.1M | 2% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
